Search Results for: Pharma: Other News to Note
-
Other News To Note
In addition to active involvement in the development of the monoclonal antibody, AET BioTech will provide additional investment in the biosimilar based on committed long-term financing and will oversee future commercialization of the product...IL-17 mediated signaling is known to induce the expression of cytokines and other effectors in a variety of immunological diseases such as psoriasis and chronic obstructive pulmonary disease...Efficacy against non-small-cell lung cancer and pharmacokinetics also -
Pharma: Other News To Note
Pfizer Inc., of New York, said the European Commission gave conditional marketing authorization for Xalkori (crizotinib) for the treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer...The alliance will facilitate research on 13 undisclosed rare disease indications and has the potential to add candidates to Shire's early stage pipeline -
Pharma: Other News To Note
Eli Lilly and Co., of Indianapolis, said the FDA approved the label inclusion for Alimta (pemetrexed) with Phase III data demonstrating progression-free survival and overall survival advantages in the continuation maintenance setting for patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer following first-line Alimta plus cisplatin -
Other News To Note
In other news, Almirall reported data from the MOVE 2 study supporting the use of Sativex, an endocannabinoid modulator, to reduce symptoms of moderate to severe spasticity due to multiple sclerosis -
Other News To Note
AspenBio Pharma Inc., of Castle Rock, Colo., said it is proposing to change its name to Venaxis Inc...Specialised Therapeutics Australia pty Ltd. (STA), of Melbourne, Australia, received exclusive commercialization rights to a ghrelin receptor agonist, anamorelin, for non-small-cell lung cancer cachexia-anorexia through an agreement with Helsinn Healthcare, of Lugano, Switzerland -
Other News To Note
LEO Pharma A/S, of Ballerup, Denmark, disclosed plans to establish five long-term, strategic research collaborations in Australia, France, Germany and the U.S...If the results of the studies are sufficiently favorable, Wassermann will have the right to exercise an exclusive option for the development and commercialization of velusetrag in the European Union, Russia, China, Mexico and certain other countries...Theravance retains full rights to velusetrag in the U.S., Canada, Japan and certain other -
Synta Sizzles on Ganetespib Phase IIb Data in Lung Cancer
The Phase IIb is designed to identify the patient population, defined by biomarker or other disease characteristic, for advancement into the Phase III portion of the trial...Biomarker findings and other patient selection and treatment experience from the Phase IIb stage will be incorporated into the design of Phase III, which the company plans to discuss with the FDA before launching the study this year, Farmer said...The two have nothing to do with each other -
Other News To Note
Curadev Pharma Private Ltd., of New Delhi, India, triggered a milestone payment from Endo Health Solutions, of Newark, Del., by advancing its oncology program to the next stage of development...oncology-focused company and a Top 20 pharma firm, in which MAB will deliver a number of monoclonal antibodies to partner-selected targets -
Other News To Note
In other news, Ablynx said it and partner Merck Serono, a division of Darmstadt, Germany-based Merck KGgA, advanced Nanobody candidate ALX-0751 into preclinical development in cancer...In other news, Boehringer and Eli Lilly and Co., of Indianapolis, said they received a positive opinion from the European Committee for Medicinal Products for Human Use for DPP-4 inhibitor Trajenta (linagliptin) in combination with insulin in adults with Type II diabetes...are soliciting consents from note holders for -
Pharma: Other News To Note
Payments to LDC could aggregate to €82.5 million (US$106.8 million) in development milestones and €55 million in sales milestones, plus royalties on any net sales...Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it submitted a marketing authorization application to the European Medicines Agency for approval of afatinib, an irreversible ErbB family blocker, as a treatment for patients with EGFR mutation-positive non-small-cell lung cancer -
Pharma: Other News To Note
Merck KGgA, of Darmstadt, Germany, said it withdrew its application from the European Medicines Agency seeking to extend the use of cancer drug Erbitux (cetuximab) in non-small-cell lung cancer -
Other News To Note
In other news, 3SBio said its special committee of independent directors has retained Cleary Gottlieb Steen & Hamilton LLP, of New York, as the committee's legal counsel...In other news, Boehringer said it started an open-label U.S...The objectives are to decrease or stabilize the number of blood-circulating CLL cells and to delay the onset of other signs of progression, such as swelling of lymph nodes, which then requires immunochemotherapy treatment -
Pharma: Other News To Note
expanded access program for investigational oncology compound afatinib, which will be available to eligible patients with locally advanced or metastatic non-small-cell lung cancer who have an epidermal growth factor receptor mutation -
Other News To Note
The pharma company agreed to offer additional benefits to employees directly affected by the restructuring, including a minimum guaranteed severance pay of CHF25,000 (US$25,600), additional severance pay for employees 50 or older and full severance pay for employees who resigned in the three months preceding their severance date...Sun Pharmaceutical Industries Ltd., of Mumbai, India, will acquire Taro Pharmaceutical Industries Ltd., of Hawthorne, N.Y., for $39.50 in cash per share paid to -
Pharma: Other News To Note
In separate news, Pfizer reported that the District Court for the District of Delaware has upheld its composition-of-matter patent and pain and seizure use patents covering Lyrica (pregabalin) capsules CV...The change follows Shire's announcement that it planned to build a regenerative medicine campus in San Diego to expand its operational footprint and presence in the area over the next several years. (See BioWorld Today, June 12, 2012 -
IPO Window Opening? Tesaro Prices Within Expected Range
One of those ALK inhibitors is TSR-011, which is in preclinical development with a plan to advance the product into clinical testing as a treatment for non-small-cell lung cancer and potentially other cancer indications...The company plans to use the proceeds to fund clinical trials, R&D activities and other corporate programs...Gemmus Pharma Inc., of San Francisco, closed a Series A round to advance its host-targeted treatment for influenza -
Other News To Note
Cytos intends to use the proceeds primarily to conduct a Phase IIb study of CYT003 in allergic asthma...Sigmoid Pharma Ltd., of Dublin, Ireland, said it completed a multicenter, placebo-controlled, randomized Phase II trial of CyCol, its lead candidate, in ulcerative colitis -
Pharma: Other News To Note
The FDA asked AstraZeneca to voluntarily withdraw Iressa in 2010 after postmarketing studies failed to verify and confirm clinical benefit...The closure will result in the elimination of about 500 positions and the relocation of 750 positions to other Merck facilities...The plan is expected to be fully implemented in the first half of 2013 -
Other News To Note
They also agreed to conduct a drug-drug interaction study, with results to guide the further evaluation of the combo regimen in hepatitis C virus patients...Mouse ALK-positive non-small-cell lung cancer xenograft models showed greater anticancer activity when treated with a combination of ganetespib and crizotinib than when either drug was administered alone -
Other News To Note
The company said the trials showed MoxDuo CR had superior performance in sustained blood levels for up to 24 hours, compared to OxyContin (sustained-release oxycodone) and MS Contin (sustained-release morphine, both Purdue Pharma LP...QRxPharma plans to initiate Phase II proof-of-concept studies midyear, with a U.S...Teijin Pharma Ltd., of Tokyo, and the Menarini Group, of Florence, Italy, said they signed a distribution agreement for the marketing of febuxostat, a nonpurine selective inhibitor of
Category
Current Filters
- xcell lung
Related Keywords
Categories
- x BioWorld Today (299)
- x BioWorld International (80)
- x BioWorld Insight (8)
- x Bio Perspectives (2)
- x State of the Industry Report (2)